All In MedTech

Device Trial Radar · NCT03284619

First-In Man (FIM) Study MR-Linac

Last checked: Nov 20, 2026Latest source record: Mar 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5

Actual

Start

Apr 1, 2017

Primary completion

Jul 11, 2017

Study completion Sep 8, 2017

Sponsor

Lead sponsor
Nucletron Operations BVNot on our public-company list
Sponsor type
Industry
Collaborators
Factory CRO for Medical Devices B.V.
First posted
Sep 15, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigational device is the Magnetic resonance imager linear accelerator. Five (5) patients with bone metastases will be treated with palliative intention in this study. The goal is to confirm the pre-clinically demonstrated technical accuracy and safety of the newly developed MR-Linac in the clinical setting.

Conditions

  • Bone Metastases

Interventions

  • Magnetic resonance imager linear acceleratorDevice

    The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of the treatment system (a dose distribution accuracy ≤ 5% will be considered acceptable). Incidence of acute toxicity (CTCAE grade 2 are higher) and incidence of Serious (unexpected) Adverse Events will be measured.Time frame: During treatment (Day 0). For patient safety patients will be contacted at day 1, week 2 and week 12 after treatment.
  2. Geometrical accuracy of targeting by online MR imagingTime frame: During treatment (day 0)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Centre Utrecht

    Utrecht, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.